Sharps Technology Inc (STSS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sharps Technology Inc stock (STSS) is currently trading at $1.73. Sharps Technology Inc PS ratio (Price-to-Sales) is 167.53. Analyst consensus price target for STSS is $22.00. WallStSmart rates STSS as Sell.
- STSS PE ratio analysis and historical PE chart
- STSS PS ratio (Price-to-Sales) history and trend
- STSS intrinsic value — DCF, Graham Number, EPV models
- STSS stock price prediction 2025 2026 2027 2028 2029 2030
- STSS fair value vs current price
- STSS insider transactions and insider buying
- Is STSS undervalued or overvalued?
- Sharps Technology Inc financial analysis — revenue, earnings, cash flow
- STSS Piotroski F-Score and Altman Z-Score
- STSS analyst price target and Smart Rating
Sharps Technology Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Sharps Technology Inc (STSS) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Sharps Technology Inc (STSS) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Sharps Technology Inc (STSS) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 167.5x annual revenue
Very low institutional interest at 0.14%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Sharps Technology Inc (STSS) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.12) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (167.53) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -6.65%, Operating Margin at -1350.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -6.65% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
STSS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
STSS's Price-to-Sales ratio of 167.53x sits near its historical average of 148.18x (69th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 85% below its historical high of 1134.93x set in Aug 2025, and 9813% above its historical low of 1.69x in Apr 2025. Over the past 12 months, the PS ratio has expanded from ~3.5x, reflecting growing market expectations outpacing revenue growth.
Compare STSS with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Sharps Technology Inc (STSS) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Sharps Technology Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Spending 68% of revenue (152,109) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -195M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.13, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Sharps Technology Inc.
Bottom Line
Sharps Technology Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Sharps Technology Inc(STSS)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes and sells safety syringes in the United States. The company is headquartered in Melville, New York.